Please enable JavaScript to continue using this application.

Compare $ERAS vs $PTCT | Chartloom

Compare

$ERAS vs $PTCT

Erasca Inc · PTC Therapeutics Inc

ERAS

Erasca Inc

PTCT

PTC Therapeutics Inc

Compare $ERAS vs $PTCT

Comparing Erasca Inc and PTC Therapeutics Inc

ERASErasca Inc

PTCTPTC Therapeutics Inc

ERASErasca Inc

Market cap

$5.49B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

346.5%

52W performance

559.7%

FCF yield

-1.8%

PTCTPTC Therapeutics Inc

Market cap

$5.37B

P/E (TTM)

—

Forward P/E (NTM)

43.00x

Forward P/S (NTM)

4.18x

Rev growth (TTM)

-36.7%

YTD performance

-15.7%

52W performance

0.3%

FCF yield

-0.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ERAS

PTCT

Detailed metrics comparison

ERAS

Erasca Inc

PTCT

PTC Therapeutics Inc

Market Cap

ERAS$5.49B

PTCT$5.37B

Enterprise Value

ERAS$5.44B

PTCT$7.24B

Price

ERAS$16.03

PTCT$64.70

P/E Ratio

ERASN/A

PTCTN/A

P/S Ratio

ERAS0.00x

PTCT5.32x

EV/Sales

ERAS0.00x

PTCT7.17x

EV/EBITDA

ERAS0.00x

PTCT35.21x

P/B Ratio

ERAS14.25x

PTCT3,530.95x

P/FCF Ratio

ERASN/A

PTCTN/A

EV/FCF

ERAS-55.50x

PTCT-182.20x

PEG Ratio

ERASN/A

PTCTN/A

Forward P/E (NTM)

ERASN/A

PTCT43.00x

Forward P/S (NTM)

ERASN/A

PTCT4.18x

Revenue (TTM)

ERAS$0

PTCT$1.01B

Revenue Growth (YoY)

ERASN/A

PTCT-36.7%

Forward Rev Growth

ERAS959.7%

PTCT11.6%

Gross Margin (TTM)

ERAS0.0%

PTCT93.0%

Operating Margin (TTM)

ERAS0.0%

PTCT12.4%

EBITDA Margin (TTM)

ERAS0.0%

PTCT17.1%

Net Margin (TTM)

ERAS0.0%

PTCT-3.8%

FCF Margin (TTM)

ERASN/A

PTCT-3.9%

Net Income (TTM)

ERAS$-287M

PTCT$-38M

FCF (TTM)

ERAS$-98M

PTCT$-40M

EPS (TTM)

ERAS-$0.92

PTCT-$0.42

ROE (TTM)

ERAS-8043.0%

PTCT-35191.0%

ROA (TTM)

ERAS-6708.0%

PTCT-132.0%

ROIC (TTM)

ERAS-8043.0%

PTCT-3977.0%

Cash

ERAS$43M

PTCT$1.05B

Debt

ERAS$0

PTCT$2.92B

Net Cash/Debt

ERAS$43M

PTCT$-1.87B

Current Ratio (TTM)

ERAS8.29x

PTCT3.39x

Quick Ratio (TTM)

ERAS8.08x

PTCT3.20x

Debt/Equity (TTM)

ERAS0.00x

PTCT848.93x

Debt/Assets (TTM)

ERAS0.0%

PTCT0.0%

Interest Coverage (TTM)

ERASN/A

PTCTN/A

Net Debt/EBITDA (TTM)

ERAS0.00x

PTCT0.00x

Beta

ERAS0.67

PTCT0.50

52W Performance

ERAS559.7%

PTCT0.3%

YTD Performance

ERAS346.5%

PTCT-15.7%

% from 52W High

ERAS-34.0%

PTCT-28.8%

% from 52W Low

ERAS661.5%

PTCT5.7%

Asset Turnover (TTM)

ERAS0.00x

PTCT0.35x

FCF Yield (TTM)

ERAS-1.8%

PTCT-0.7%

Earnings Yield (TTM)

ERAS-5.2%

PTCT-0.7%

Dividend Yield (TTM)

ERASN/A

PTCTN/A

Rule of 40

ERAS0.0

PTCT-40.7

EV/GP/RG

ERASN/A

PTCT0.24

Ticker research

View ERAS research View PTCT research

Metric	ERAS Erasca Inc	PTCT PTC Therapeutics Inc
Market & Valuation
Market Cap	$5.49B	$5.37B
Enterprise Value	$5.44B	$7.24B
Price	$16.03	$64.70
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	5.32x
EV/Sales	0.00x	7.17x
EV/EBITDA	0.00x	35.21x
P/B Ratio	14.25x	3,530.95x
P/FCF Ratio	N/A	N/A
EV/FCF	-55.50x	-182.20x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	43.00x
Forward P/S (NTM)	N/A	4.18x
Revenue & Growth
Revenue (TTM)	$0	$1.01B
Revenue Growth (YoY)	N/A	-36.7%
Forward Rev Growth	959.7%	11.6%
Profitability
Gross Margin (TTM)	0.0%	93.0%
Operating Margin (TTM)	0.0%	12.4%
EBITDA Margin (TTM)	0.0%	17.1%
Net Margin (TTM)	0.0%	-3.8%
FCF Margin (TTM)	N/A	-3.9%
Net Income (TTM)	$-287M	$-38M
FCF (TTM)	$-98M	$-40M
EPS (TTM)	-$0.92	-$0.42
ROE (TTM)	-8043.0%	-35191.0%
ROA (TTM)	-6708.0%	-132.0%
ROIC (TTM)	-8043.0%	-3977.0%
Financial Health
Cash	$43M	$1.05B
Debt	$0	$2.92B
Net Cash/Debt	$43M	$-1.87B
Current Ratio (TTM)	8.29x	3.39x
Quick Ratio (TTM)	8.08x	3.20x
Debt/Equity (TTM)	0.00x	848.93x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	0.50
52W Performance	559.7%	0.3%
YTD Performance	346.5%	-15.7%
% from 52W High	-34.0%	-28.8%
% from 52W Low	661.5%	5.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.35x
FCF Yield (TTM)	-1.8%	-0.7%
Earnings Yield (TTM)	-5.2%	-0.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-40.7
EV/GP/RG	N/A	0.24
Ticker research	View ERAS research	View PTCT research

Valuation

P/S Ratio

ERAS

0.00x

PTCT

5.32x

EV/FCF

PTCT

-182.20x

ERAS

-55.50x

Growth & revenue

Revenue Growth TTM

PTCT

-36.7%

Forward Revenue Growth

ERAS

959.7%

PTCT

11.6%

Profitability & performance

Gross Margin

PTCT

93.0%

ERAS

0.0%

ROE

ERAS

-8043.0%

PTCT

-35191.0%

FCF Yield %

PTCT

-0.7%

ERAS

-1.8%

52-Week Performance

ERAS

559.7%

PTCT

0.3%

Detailed metrics comparison

ERAS

Erasca Inc

PTCT

PTC Therapeutics Inc

Market Cap

ERAS$5.49B

PTCT$5.37B

Enterprise Value

ERAS$5.44B

PTCT$7.24B

Price

ERAS$16.03

PTCT$64.70

P/E Ratio

ERASN/A

PTCTN/A

P/S Ratio

ERAS0.00x

PTCT5.32x

EV/Sales

ERAS0.00x

PTCT7.17x

EV/EBITDA

ERAS0.00x

PTCT35.21x

P/B Ratio

ERAS14.25x

PTCT3,530.95x

P/FCF Ratio

ERASN/A

PTCTN/A

EV/FCF

ERAS-55.50x

PTCT-182.20x

PEG Ratio

ERASN/A

PTCTN/A

Forward P/E (NTM)

ERASN/A

PTCT43.00x

Forward P/S (NTM)

ERASN/A

PTCT4.18x

Revenue (TTM)

ERAS$0

PTCT$1.01B

Revenue Growth (YoY)

ERASN/A

PTCT-36.7%

Forward Rev Growth

ERAS959.7%

PTCT11.6%

Gross Margin (TTM)

ERAS0.0%

PTCT93.0%

Operating Margin (TTM)

ERAS0.0%

PTCT12.4%

EBITDA Margin (TTM)

ERAS0.0%

PTCT17.1%

Net Margin (TTM)

ERAS0.0%

PTCT-3.8%

FCF Margin (TTM)

ERASN/A

PTCT-3.9%

Net Income (TTM)

ERAS$-287M

PTCT$-38M

FCF (TTM)

ERAS$-98M

PTCT$-40M

EPS (TTM)

ERAS-$0.92

PTCT-$0.42

ROE (TTM)

ERAS-8043.0%

PTCT-35191.0%

ROA (TTM)

ERAS-6708.0%

PTCT-132.0%

ROIC (TTM)

ERAS-8043.0%

PTCT-3977.0%

Cash

ERAS$43M

PTCT$1.05B

Debt

ERAS$0

PTCT$2.92B

Net Cash/Debt

ERAS$43M

PTCT$-1.87B

Current Ratio (TTM)

ERAS8.29x

PTCT3.39x

Quick Ratio (TTM)

ERAS8.08x

PTCT3.20x

Debt/Equity (TTM)

ERAS0.00x

PTCT848.93x

Debt/Assets (TTM)

ERAS0.0%

PTCT0.0%

Interest Coverage (TTM)

ERASN/A

PTCTN/A

Net Debt/EBITDA (TTM)

ERAS0.00x

PTCT0.00x

Beta

ERAS0.67

PTCT0.50

52W Performance

ERAS559.7%

PTCT0.3%

YTD Performance

ERAS346.5%

PTCT-15.7%

% from 52W High

ERAS-34.0%

PTCT-28.8%

% from 52W Low

ERAS661.5%

PTCT5.7%

Asset Turnover (TTM)

ERAS0.00x

PTCT0.35x

FCF Yield (TTM)

ERAS-1.8%

PTCT-0.7%

Earnings Yield (TTM)

ERAS-5.2%

PTCT-0.7%

Dividend Yield (TTM)

ERASN/A

PTCTN/A

Rule of 40

ERAS0.0

PTCT-40.7

EV/GP/RG

ERASN/A

PTCT0.24

Ticker research

View ERAS research View PTCT research

Metric	ERAS Erasca Inc	PTCT PTC Therapeutics Inc
Market & Valuation
Market Cap	$5.49B	$5.37B
Enterprise Value	$5.44B	$7.24B
Price	$16.03	$64.70
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	5.32x
EV/Sales	0.00x	7.17x
EV/EBITDA	0.00x	35.21x
P/B Ratio	14.25x	3,530.95x
P/FCF Ratio	N/A	N/A
EV/FCF	-55.50x	-182.20x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	43.00x
Forward P/S (NTM)	N/A	4.18x
Revenue & Growth
Revenue (TTM)	$0	$1.01B
Revenue Growth (YoY)	N/A	-36.7%
Forward Rev Growth	959.7%	11.6%
Profitability
Gross Margin (TTM)	0.0%	93.0%
Operating Margin (TTM)	0.0%	12.4%
EBITDA Margin (TTM)	0.0%	17.1%
Net Margin (TTM)	0.0%	-3.8%
FCF Margin (TTM)	N/A	-3.9%
Net Income (TTM)	$-287M	$-38M
FCF (TTM)	$-98M	$-40M
EPS (TTM)	-$0.92	-$0.42
ROE (TTM)	-8043.0%	-35191.0%
ROA (TTM)	-6708.0%	-132.0%
ROIC (TTM)	-8043.0%	-3977.0%
Financial Health
Cash	$43M	$1.05B
Debt	$0	$2.92B
Net Cash/Debt	$43M	$-1.87B
Current Ratio (TTM)	8.29x	3.39x
Quick Ratio (TTM)	8.08x	3.20x
Debt/Equity (TTM)	0.00x	848.93x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	0.50
52W Performance	559.7%	0.3%
YTD Performance	346.5%	-15.7%
% from 52W High	-34.0%	-28.8%
% from 52W Low	661.5%	5.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.35x
FCF Yield (TTM)	-1.8%	-0.7%
Earnings Yield (TTM)	-5.2%	-0.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-40.7
EV/GP/RG	N/A	0.24
Ticker research	View ERAS research	View PTCT research